Last reviewed · How we verify
Depsipeptide, FR901228, FK228
At a glance
| Generic name | Depsipeptide, FR901228, FK228 |
|---|---|
| Sponsor | National Cancer Institute (NCI) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Fatigue
- Constipation
- Anorexia
- Thrombocytopenia
- Vomiting
- Pyrexia
- Neutropenia
- Diarrhoea
- Dysgeusia
- Headache
- Vomiting NOS
Key clinical trials
- Study of Pembrolizumab (MK-3475) in Combination With Romidepsin (PHASE1, PHASE2)
- Romidepsin Maintenance After Allogeneic Stem Cell Transplantation (PHASE1)
- Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (PHASE1)
- Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer (PHASE1, PHASE2)
- Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (PHASE1)
- Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas (PHASE1)
- Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma (PHASE2)
- Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Depsipeptide, FR901228, FK228 CI brief — competitive landscape report
- Depsipeptide, FR901228, FK228 updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI